Moderna and Merck released Phase 3 trial results showing their personalized mRNA cancer vaccine, combined with Keytruda, reduces melanoma recurrence or death risk by 42% compared to Keytruda alone. Specialists see this as a significant breakthrough that could become standard post-surgery care, potentially preventing metastatic disease and improving patient outcomes. Despite a stock sell-off due to investor expectations, experts highlight the vaccine's clinical promise and mild side effects. Further data will be presented at a medical conference, and regulatory approval is expected next year.
Moderna's stock trades at USD 203.33 with a slight 0.35% gain on Pluang as of Oct 23, 2026 22:41 WIB, despite the article noting a sell-off. Merck shares are down 1.70% at USD 144.74 on Pluang during the same time frame. The platform shows significant sell pressure with 71% of orders selling Moderna and 63% selling Merck, reflecting cautious investor sentiment around these health sector leaders.
Moderna's stock dropped 4% following an earlier 18% plunge after the release of positive late-stage results for its personalized melanoma vaccine co-developed with Merck. Although the vaccine showed a reduction in melanoma recurrence risk, the result...
Moderna's shares fell nearly 18% after positive Phase 3 results for its personalized melanoma vaccine with Merck were leaked early, causing market uncertainty despite the promising data. Meanwhile, SpaceX is negotiating with major infrastructure firm...
Moderna's stock dropped sharply by over 21% in two days following the leak of early Phase 3 trial results for its personalized cancer vaccine and a major downgrade from Citi, which issued a 'Sell' rating and an $80 price target. Despite the leaked re...
Moderna's stock fell up to 25% following the leak of partial data on its cancer vaccine developed with Merck, despite the full phase 3 trial results later showing positive outcomes. The vaccine, combined with Merck's Keytruda, reduced the risk of mel...
Moderna's stock fell sharply by 25% following an unauthorized leak of Phase 3 data for its experimental cancer vaccine developed with Merck. The data was expected to be officially presented at a medical conference this weekend. Merck's shares also de...
